YOUR DAILY PEPTIDE BRIEFING / SCIENCE / COMMUNITYNew source checks every six hours
Daily Peptide StackNEWS • RESEARCH • COMMUNITY
THE NEWS STACK / SOURCE NOTE

In T2D, combined SGLT2i + GLP-1 RA vs. either alone does not reduce MACE or renal outcomes..

A source-backed record from the peptide news monitor, with the original source linked below.

BEFORE YOU READ

This page links to the original record; it is not an independent analysis or clinical recommendation.

← Back to Research Stack
Research StackPubMed (NCBI)

In T2D, combined SGLT2i + GLP-1 RA vs. either alone does not reduce MACE or renal outcomes.

A recently indexed PubMed record relevant to peptide research. The displayed date may reflect indexing rather than final print publication. Review the original citation and study limitations.

Open original source ↗

Collected Nov 3, 2026. Third-party data may change. Consult the original publication or registry for complete methods, findings and status.